Skip to main content

Table 1 Characteristics of patients undergoing CEA depending on occurrence of symptoms and undergoing CABG

From: DNA methylome profiling reveals epigenetic regulation of lipoprotein-associated phospholipase A2 in human vulnerable atherosclerotic plaque

 

LIMA (n = 4)

ASYM (n = 8)

SYM (n = 6)

p value

Age (years)

68.8 ± 5.4

70.3 ± 7.3

71.8 ± 9.0

0.818

Males (%)

4 (100.0)

8 (100.0)

6 (100.0)

1.000

Smokers (%)

2 (50.0)

6 (75.0)

3 (50.0)

0.569

CHD (%)

4 (100.0)

5 (62.5)

4 (66.7)

0.529

Hypertension (%)

4 (100.0)

4 (50.0)

5 (83.0)

0.207

Diabetes (%)

2 (25.0)

2 (25.0)

4 (66.7)

0.344

Fasting lipoproteins, (mmol/L)

 Total cholesterol

3.5 ± 1.2

4.9 ± 1.3

4.1 ± 1.7

0.266

 LDL cholesterol

2.2 ± 1.3

2.8 ± 1.2

2.6 ± 1.9

0.469

 HDL cholesterol

0.7 ± 0.2

1.4 ± 0.4

1.5 ± 0.6

0.055

 Triglycerides

1.4 ± 0.2

1.9 ± 0.8

1.5 ± 1.0

0.568

Aspirin (%)

4 (100.0)

8 (100.0)

6 (100.0)

1.000

Statin (%)

4 (100.0)

4 (50.0)

5 (83.3)

0.207

  1. CEA carotid endarterectomy, CABG coronary artery bypass  graft, LIMA left internal mammary artery, SYM symptomatic, ASYM asymptomatic, LDL low density lipoprotein, HDL high density lipoprotein